Showing results (41-50 of 172) with videos related to
Sort By:
Pageof 18
Leukemia & Lymphoma|October 27, 2006
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphomaBarbara Pro, Fredrick B Hagemeister, Peter McLaughlin, et al.Leukemia & Lymphoma|January 7, 2006
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphomaBarbara Pro, Luis Fayad, Peter McLaughlin, et al.Cancer|December 19, 2007
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphomaYasuhiro Oki, Barbara Pro, Luis E Fayad, et al.Journal of the American Academy of Dermatology|July 6, 2017
CD8<sup>+</sup> mycosis fungoides: A low-grade lymphoproliferative disorderMaria Estela Martinez-Escala, Robert W Kantor, Ahuva Cices, et al.Neuro-Oncology Practice|May 31, 2021
Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapyNa Tosha N Gatson, Mina Makary, Shane P Bross, et al.Ejhaem|February 23, 2023
Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphomaReem Karmali, Frederique St-Pierre, Shuo Ma, et al.Cancer|January 12, 2013
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomasJane E Churpek, Barbara Pro, Koen van Besien, et al.JAMA Dermatology|June 7, 2018
Hemophagocytic Lymphohistiocytosis in Cutaneous T-Cell LymphomaDylan E Lee, M Estela Martinez-Escala, Linda M Serrano, et al.Cancer|May 15, 2007
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphomaElias Jabbour, Chitra Hosing, Gregory Ayers, et al.British Journal of Haematology|February 10, 2022
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphomaIshan Roy, Gordon Smilnak, Madelyn Burkart, et al.Pageof 18